CARMAT (FR0010907956, ALCAR, PEA-PME eligible), designer and developer of the most advanced total artificial heart project in the world, aimed at offering a therapeutic alternative to patients suffering from end-stage biventricular heart failure, informs its shareholders that the Mixed General Meeting (AGM) of May 11, 2022 was able to validly deliberate, the quorum having been reached.
The AGM adopted all the proposed resolutions, with the exception of the 43rd resolution which was rejected, in accordance with the recommendations of the Board of Directors.
The company’s shareholders notably approved the reduction of the term of office of directors from 6 to 3 years, and the renewal of the terms of office of directors proposed according to these new terms.
The Board of Directors is thus composed of 11 members, 7 of whom are independent, with terms of office expiring at the end of the ordinary general meeting to be held in 2025.
CARMAT would like to thank all the shareholders present, represented or having voted by post for their commitment and support.
The consolidated result of the vote by resolution and the minutes of the AGM of May 11, 2022 will be available on the Company’s website, under Regulated information / General meetings, within the legal deadlines.
To receive all of CARMAT’s financial information in real time, send a request by email to [email protected] Your registration will be immediate.